Immune Checkpoint Inhibitors and Lupus Erythematosus
Immune checkpoint inhibitors (ICIs) are the standard of care for a growing number of malignancies. Unfortunately, they are associated with a broad range of unique toxicities that mimic the presentations of primary autoimmune conditions. These adverse events are termed immune-related adverse events (...
Saved in:
Main Authors: | Hans Vitzthum von Eckstaedt (Author), Arohi Singh (Author), Pankti Reid (Author), Kimberly Trotter (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics
by: Michael Macklin, et al.
Published: (2023) -
Immune Checkpoint Inhibitors New Insights and Recent Progress
Published: (2023) -
The gut microbiota and immune checkpoint inhibitors
by: Audrey Humphries, et al.
Published: (2018) -
Cardiovascular complications of immune checkpoint inhibitors
by: A. A. Kulievа, et al.
Published: (2020) -
Topical calcineurin inhibitors in systemic lupus erythematosus
by: Christos E Lampropoulos, et al.
Published: (2010)